The genetic and genomic background of multiple myeloma patients achieving complete response after induction therapy with bortezomib, thalidomide and dexamethasone (VTD)

The prime focus of the current therapeutic strategy for Multiple Myeloma (MM) is to obtain an early and deep tumour burden reduction, up to the level of complete response (CR). To date, no description of the characteristics of the plasma cells (PC) prone to achieve CR has been reported. This study a...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncotarget
Main Authors: Terragna, Carolina, Remondini, Daniel, Martello, Marina, Zamagni, Elena, Pantani, Lucia, Patriarca, Francesca, Pezzi, Annalisa, Levi, Giuseppe, Offidani, Massimo, Proserpio, Ilaria, De Sabbata, Giovanni, Tacchetti, Paola, Cangialosi, Clotilde, Ciambelli, Fabrizio, Viganò, Clara Virginia, Dico, Flores Angela, Santacroce, Barbara, Borsi, Enrica, Brioli, Annamaria, Marzocchi, Giulia, Castellani, Gastone, Martinelli, Giovanni, Palumbo, Antonio, Cavo, Michele
Formato: Artigo
Idioma:Inglês
Publicado em: Impact Journals LLC 2015
Assuntos:
Research Paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4891075/
https://ncbi.nlm.nih.gov/pubmed/26575327
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.5718
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados